PTO/NAM 4- (12—13)
`App-raved Ear use through 01/31/2014. OMB 0551-0032
`US, Patent and 'i'rademark Office; US. DEPARTMENT OF COMMERCE
`Under ihe Paperwork Reduciieri Act of 1995. no persens are required to. respond in a eoEiectien of inferma’rion uniess it caniairis a vaiid OMB coniroi number.
`
`EAanicetion Number
`
`Suprenorphine—Wafer for Drug Substitution Therapy
`: TEi‘Ee 0E invention
`
`
`Therapp *afion daEiShQVJSEl
`.thneErovn40raiernunrrowsLnaianHC . nfi3rwhu:hiiL )ewu;subnwifie:i Thrflfo Grungkvn“runhnrsthn
`
`bmmnmmcdmeanmmmflnefixmahme“idbymeUandsmmsemn‘ cndTndmmnkQficresmflmmhn37vFRi75
`
`ENSdmmmemnmybemmmmmdemdmn
`vamwaWMHLomoQficonokdnm‘"nmfiunmflh FdethMQSwn
`E decumentmaybeganMENwindudedinepapermed eppEK:efion.
`
`emEEFS‘Knmze
`
`E5eereey Garner 3‘? CFR 52
`I............................................................................................................................................................................................................................................................C............................
`E: Port"sons or 31: of the epphEcatior: assoc:-ated with this AppiELetien Data Sheet may faii under a SecrLLy Order pursuant to
`37 CPR 5.2 (Paper fliers eniy. Appiiceiiens that feii under Secrecy Order may net be fiied eiectreniceiiy.)
`
`invenier inierrneiien:
`
` invenier
`1
`E Legei Name
`
`Prefix— Minnie Name
`
`Femiiy Name
`
`ESn‘i‘iix
`
`Residence information (Seieet Gne) {:ii Sixesidency @ Non US Residencv 0 Active US MiEiiery Service
`ECouniry 01' Residence ‘
`ECii‘y
`Limburg
`
`Eiiiieiiing Address of invenier:
`
`E Adriress‘i
`
`Birkenstr. 22
`
`
`
`
`E Kéi'éiiéé'QE'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
`
`
`
`:
`inventor
`2
`. Legai Name
`
`Famiiy Name
`Prefixllii— iiiiicir‘iie Name
` HEATH
`Residence infermaiien {Seieet One) 0 US Residency
`(6;) Non US Residency O Aciive LS MEEiterry Service
`ECeuntry Of Residence E
`ECEiy
`Cambridge
`
`ESui’iix
`
`Eiiiieiiing Address 51 inventor:
`
`
`E Address ’i
` . Address 2
`
`do Napp Pharmaceuticeis Limited
`
`Cambridge Science Park, Miiien Read
`
` invenier
`3
`E Legei Name
`
`EFS Web 2.2.11
`
`

`

`PTO/NAM 4. (12—13)
`App-raved fat use through 01/31/2014. OMB 0651-0032
`US, Patent and trademark Office; US, DEPARTMENT OF COMMERCE
`Under the Paperwork Reduciimt Act of 1995. no persc-ns are required to, respond to a coiiectEc-n 0f infc-rmatieri urtiess it cuntairts a valid OMB central number.
`
`E
`EAtterney Docket Number
`1861 ZYOGOOi/JNEC'MSB
`
`
`EAppiieetiert Sate Sheet 3'? CFR 1”ME-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`.
`EAppiiceiiort Number
`
`
`
`
`Titie 0f invention
`ils‘uprenorphine-Waferfer Drug Substitutiom Therapy
`
`
`Ei’xourrtry of Residence ‘
`
`EEAcicireee ‘E
`EAddress 2
`
`City
`
`Paetaieoee
`
`inventor
`
`A
`
`liege: Name
`
`(:10 New Pharmaceuticais Limited
`Cam bridge Science P "' M'iton Road
`
`
`Cambrdige
`
`Stateiprevince
`
`CB4 new
`
`Cuuntryi
`
`GB
`
`
`
`Prefix—A;Middie Name
`
`Famiiy Name
`
`ESufiix
`
`Residence intermetien (Seiect One) GUS Residency
`
`@2 Non US Residency 0 Active US Mi-:itarysewice
`
` Address 1
`0/0 N'Eundipi‘terrne Research Limited
`Adtiress 2
`Cambridge Science Park, N'iiiitori Road
`
`City
`
`Cambridge
`
`StateiPrevinee
`
`inventer
`
`5
`
`E Legai Name
`
`
`
`ESufiix
`Femiiy Name
`Prefix'— Middie Name
`—®—__
`C; Non US Residency Q Active US N’ii'Eitery Service
`
`
`Reeirzierree Enfermetien (Seiect Qne) QUE Residency
`
` E Address’i
`Addreeez
`r__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
`City
`Greenwich
`Stateiprevince
`CT
`
`EFS Web 221‘:
`
`

`

`PTO/NAM 4- (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and 'i'rademark Office; US, DEPARTMENT OF COi‘riit’iEi—ZCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a coiiection of information untess it contains a valid OMB control number.
`
`
`Attorney Docket Number
`1861.2700001/JMCIMSB
`..
`‘
`Apniieatren {Beta Street 3'? CFR 1.276 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`Appiioation Number
`
`
`Titie of invention
`Buprenorphine-Waferfor Drug Substitution Therapy
`
`.-................................................................................................................................................................................................................
`
`
`
`I :
`
`6
`inventor
`
`
`Legai Name
`
`Prefix— Middie Name
`
`Famiiy Name
`
`Suffix
`
`Residence information {Seieet One) Q US Residency
`(g) Non US Residency 0 Active US Miiiiery Service
`
`ECity
`Cambridge
`ECountry of Residence 3
`
`iMaiiing Address et inventor:
`
`........................................................................................................................................................................................................................................................................................
`Address 1
`0/0 Mundipharma Research Limited
`
`
`
`Cambridge Science Park, Miiton Road
`
`Address 2
`
`inventors iviust Be Listed — Additionai inventor information biocks may he
`Aii
`generated within this form by seiecting the Add button.
`
`V
`
`
`Qorrespeneenee intermation:
`
`
`Enter either Customer Number or eernpiete the Correspondence information section beiow.
`For further inferrnatien see 3? CFR1.33(a).
`
`i.........................................................................................................................................................................................................................................................................................
`
`Emeii Address
`
`
`Appiieatien tntormatien:
`
`Titie of the inventien
`
`
`Buprenorphine—Waterfor Drug Substitution Therapy
`
` Attorney Becket Number; 1861.2700001/JMCIMSB
`
`Smaii Entity Status Claimed
`[:i
`
`
`
`Appiieetien Type
`
`Nonpr0\ii3i0nai
`
`Subject Matter
`
`Utiiity
`
`Tetai Number ef Brewing Sheets (it any)
`
`EFiting 8y Reterense:
`
`iGniy conspiete this section when fiiing an aopiication by reference under 35 U511 Ti 1(a) and 37' CFR 157(a). Do not complete this section it
`iappiication papers inciuo‘ing a specification and any drawings are being area Any domestic benefit or foreign priority information must be
`iprovided in the appropriate sectionts) beiow (Le, "Domestic Benefit/Nationai Stage information" and "Foreign Priority information”).
`
`Suggestetfi Figure for Pubiication (it any) -
`
`
`EFor the purposes of a fiiing data under 37CFR1r53(b),the description and any drawings ofthe present appiication are replaced by this
`ireference to the previousiy
`eo' application, subject to. cond ons and requirements of 37 CFR “5.517(3).
`
`
`
`
`Application number of the prev
`Fiiing date \
`‘r’Y‘r’-MM-DD)
`fiied appiication
`
`
`
`inteiiectoai Property Authority or Country
`
`
`
`EFS Web 221‘:
`
`

`

`PTO/NAM 4. (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and 'i'rao‘emark Office; US, DEPARTMENT OF COE‘.I‘:N’!ERCE
`Under the Paperwork Reduction Act of 1995. no persons are. required to respond to a ooiieotion of information uniess it contains a valid OMB control number.
`
`EAttorney Docket Number
`1861 ZYOGOOi/JNiC'MSB
`
`
`Aooiioetion nae Sheet 3'? cent. "re:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`EApoiioetion Number
`
`
`
`
`Titie of invention
`Buprenornhine-Weferfor Drug Substitution Thereby
`
`
`
`
`F’ubiioetion information:
`
`CE Request Eeriy Pubtioetion (Fee required at time of Request 3? CFR 1.219)
`
`E_,
`'
`
`i
`
`RQQNQS‘E NQE t6 Pubiieh. i hereby request that the attached apptioetion not be pubiisheo under
`35 USC. 1220)) and certify that the invention disoioeed in the attached appiioetion has not anti wiii not be the
`subject of an appiio'ation ‘tiied in another country, or under a rnuitiiater'ai internationai agreement. that requires
`pubiioation at eighteen months after tiiing.
`
`Reoreeentetive information:
`
`Representative information ehouid be provided for eii practitioners having a power of attorney in the appiioetion. Providing
`this information in the Appiioation Data Sheet does not constitute a power of attorney in the apoiioation {see 3? CFR 1.32)
`Either enter Customer Number or oompietethe Representative Name section beiow. if both sections are compieteu the customer
`Numberwiii be u3ed-for the Reoreeentative information during ,orooesei:tg.
`
`
`
`
`
`
`
`
`
`Pieese Seiect One:
`Cs) Customer Number
`0 US Patent Practitioner 0 Limited Recognition (3.7 CFR 11.9)
`
`
`{tomeetio Benetitihietionei Stage information:
`EThis section aiiows tor the appiit’ant to either {taint benefit under 35 U.S.C. itQ-(e), 126, Hi, or 365(c)- or indicate Nationai Stage
`Eentry from a PCT appiicetion. Providing this information in the appiication data sheet constitutes the specific reference required
`Eby 35 U.S.C.’i19(e)or12t), and 37 CFR 178.
`EWheh referring to the current eppiication, piease ieeve the appiication number biank.
`t____________________________________________________________________________________________________________________________________________________________________________________________________________________________
`
`Prior Appiioetion $tatus
`
`Pending
`
`
`
`Appiio'ation Number
`
`Continuity Type
`
`Prior Apoiioetion Number
`
`Fiiing Date (YYYY-Mtv’i—DD)
`
`Aopiioation Number
`1 2439410
`
`2007—08—29
`
`
`Prior Appiicetion Number
`Fiiing Date (YYW—iv’tiv‘iwDD)
`PCTIEPJZGOT/‘OESQ‘YS
`
`Continuity Type
`or 37‘: or" internetionai
`
`Additionei Domestic Benetit’t‘iationai Stage Data may be generated within this form
`by seieoting the Add button.
`
`Foreign Priority information:
`
`EFS Web 221‘:
`
`

`

`PTO/AiA/t 4. (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and trademark Office; US, DEPARTMENT OF COi‘r‘iMEi—ZCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a coiiection of information Uiiiess it contains a vaiio‘ OMB controi number.
`
`EAttorney Docket Number
`1861 2700001/JN16'MSB
`
`
`EApniieatien iiiata Sheet 3'? CFR ire:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`.
`EAppiication Number
`
`
`
`
`Titie of invention
`Buprenorphine-Waferfor Drug Substitution Therapy
`
`.-.......................................................................................................................................................................................................................................................................................
`
`This section aiiows tor the applicant to ciaim priority to a foreign appiication. Providing this information in the appiication data sheet
`Econstitutes the ciaim for priority as required by 35 U513. 11%)) and 3? CFR 1.55(o). When priority is ciairned to a foreign anpiication
`Etnat is eiigibie for retrievai under the priority document exchange program (PDXEE the information wiii be used by the Office to
`Eautomaticaiiy attempt retrievai pursuant to 37 CFR 1.550130) and (2). Under the PBX program, eppiicant bears the intimate
`Er’esponsitaiiity for ensuring that a copy of the foreign apniicetion is received by the Office from the participating foreign inteiiectuei
`Eproperty office. or a certified copy ofthe foreign priority appiication is fiied. within the time period specified in 3'? CFR 1.55(g)(‘i ).
`
`I E
`
`Appiication Number
`
`Country:
`
`Fiiing Date (YYYY—iviivi—DD)
`
`
`Access Codeitif appiicabie)
`
`Additionai Foreign Priority Data may be generated within this form by seiecting the
`Aoiri button.
`
`etatement tinder 3'? CFR 1.55 or 1.?8 for AiA (First inventor to trite) Transition
`Aepiieations
`
`.-.......................................................................................................................................................................................................................................................................................
`
`i
`
`This appiicetion (i) ciaims priority to or the benefit of an appiication fiied before iviarch 16, 2013 and (2) aiso
`contains, or contained at any time, a ciairn to a ciairried invention that has an effective i’iiing date on or after March
`E:E 18, 2013.
`NGTE: By providing this statement under 37 CFR i.55 or 1.78, this appiication, with a fiiing date on or after iviarch
`E
`“in, 2013, wiii he examined under the first inventor to fiie provisions of the AiA.
`
`Authorization to Permit Aeeess:
`
`Authorization to Permit Access to the instant Appiication by the Participating Offices
`
`
`
`EFS Web 2211
`
`

`

`PTO/NAM 4. (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and trademark Office; US, DEPARTMENT OF COi‘v‘ilViEl—ZCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`ODOO'l/JMCI’MSB
`
`k
`
`
`
`
`
`
`
`
`u
`
`
`I!
`\
`.x.
`..
`\J
`\J\
`u
`\.
`..
`..~
`.
`L.
`,..
`v.
`x...
`y
`
`.e Japan Patent Office (JPO), the Korean intellectuai Property Office (KiPO), the World inteiiecttiai Property Office (WEPO),
`nd any other intellectual property offices in which a foreign appiioation claiming priority to the instant patent appiication
`filed access to the instant patent application. See 37 CPR 1.14ic) and (h). This box should not be checked if the applicant
`
`: oes not wish the EPO, JPO, KlPOV WiPOV or other intellectual property office in which a foreign appiication claiming priority
`ito the instant patent appiicatlon is fiied to have access to the instant patent application.
`
`
`accordance with 37 CFR 1.14(h_‘,-(3), access wiii be provided to a co 3/ of the instant patent application with respect
`: 1} the instant patent application—as~r’iled; 2) any foreign application to which the instant patent application
`
`aims priority under 35 USC. ‘i19(a)—(d) if a copy of the foreign application that satisfies the certified copy requirement of
`:37 Cit-"R 1.55 has been filed in the instant patent appiication; and 3) any US. application~as~tiied from which benefit is
`isought in the instant patent appiication.
`
`
`. accordance with 37 CFR ’i.‘i4(c), access may he provided to information concerning the date o f fiiing this Authorization.
`
`
`
`Appiicant information:
`
`
`. Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`
`1
`E Appilcant
`the applicant is the inventor (or the remaining joint inventor or inventors under 37’ Ci—‘R 1.45), this section should not be cornpieted.
`he information to be provided in tins section is the name and address of the legal representative who is the applicant under 37 CFR
`.43; or the name and address or’ the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`
`'ho otherwise shows sufficient proprietary interest in the matter who is the applicant under 3‘? CFR 1.46. if the appiicant is an
`
`ppiicant under 37’ (Di-7R 146 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`roprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`
`entitled in this section.
`
`
`
` i® Aggionee
`
`O Legai Representative under 35 USE. 1‘i7
`
`0 Joint inventor
`
`EC} Person to whom the inventor is ohiigated to assign.
`
`if)
`
`Person who shows sufficient proprietary interest
`
`llf appilcant is the legal representative, indicate the authority to fiie the patent application, the inventor is:
`
`Name of the Deceased or Legally incapacitated inventor
`
`if the Applicant is an Organization check here.
`
`E}
`
`
`
`
`Address 1
`
`Address 2
`
`
`
`Phone Number
`
`EFS Web 2211
`
`Fax Number
`
`

`

`PTO/NAM 4- (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and trademark Office; US, DEPARTMENT OF COi‘r‘iMEi—ZCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a coiieotioh of information Uiiiess it contains a valid OMB control number.
`
`EAttorney Docket Number
`1861 ZYOGOOi/JNiC'MSB
`
`
`EAoniieatien {Beta Sheet 3'? CFR ’i"re:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`.
`EAppiieation Number
`
`
`
`
`Buprenorphine-Waferfor Drug Substitution Therapy
`Titie of invention
`
`..-.......................................................................................................................................................................................................................................................................................
`
`Emaii Address
`
`
`. E
`
`Aciditionai Appiioant Data may be generated within this form by seiecting the Add button.
`
`
`i
`
`Assignee information ineinding NonmApeiieant Assignee tntorrnation:
`
`EProviding assignment information in this section does not subsitute for compiiance with any requirement of part 3 of Titie 37 of CFR to
`Ehave an assignment recorded by the Office.
`
`Aseignee
`
`“i
`
`EComniete this section it assignee information, inoiuding noneppiioantassignee informationJsdesired to beinn:'L:ded on the patent
`Eappiioation publication . An assignee-appiioant identified in the "Appii cant informatflon section will appear on the patent appiication
`Epnbiication as an appiieant. For an assignee~appiicant. sompiete this section oniy it identification as an assighee is aiso desired on the
`Epatent anpiioation pubiieation.
`
`if the Assignee or Non—Apphoant Assignee is an Organization a heck here
`
`..........................................................................................................................................................................................................................
`
`Eitfiaiiing Address information For Assignee ineiuding NonnAppiieant Assignee:
`i--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- g
`Address 1
`
`Countryi
`
`Emaii Address
`
`Postai Code
`
`
`
`Additionai Assignee or Non~Appiioant Assignee Data may be generated within this form by
`seiecting the Add button.
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CPR 1.4 for signature requirements and
`certifications.
`
`Signature
`
`
`
`[Matthew s. Bodenstein/ Date (WWW—DD)—
`
`
`
`.
`I
`58885
`Registration Number
`Bodenstein
`Last Name
`Matthew S.
`FirstNarne
`
`l...............................................................................................................................................................................I......................................................................................................
`
`Additionai Signature may be generated within this term by seieeting the Add button,
`
`EFS Web 2211
`
`

`

`PTOIIAiA/14 (12—13)
`Approve-:1 for use through 01/31/2014. OMB 0651-0032
`US, Patent and Trademark Office; US, DEPARTMENT OF COi‘J‘iMEi—ZCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a coilection of information uniess it contains a valid OMB controi number.
`
`
`1861.2700001/JMCIMSB
`Attorney Docket Number
`..
`‘
`Apeiioation Data Sheet 3'? CFR 1.276 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
`
`Appiioation Number
`
`
`Titie of invention
`Buprehorphine-Waferfor Drug Substitution Therapy
`
`
`This coiieotion of information is required by 317 CFR 176. The information is required to obtain or retain a benefit by the pubiio which
`is to fiie (and by the USPTO to nrooess) an appiication. Confidentiality is governed by 35 USED. 12:? and 37’ (IF-R 1.14. This
`collection is estimated to take 23 minutes to corripiete, including gathering, preparing, and submitting the completed appiicatiori data
`sheet form to the USPTO. Time wiii vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/er suggestions for reducing this burden, should be sent to the Chief information Officer, US Patent and
`Trademark Office, US. Department of Commerce, T31). Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEE-.53 OR
`COMPLETED FORMS TO Ti-iiS ADDRESS. SEND TO; Commissioner for Patents, PD. Box 145%, Aiexandria, VA 22313-1450.
`
`EFS Web 2211
`
`

`

`titrivacy Act Statement
`
`,.
`
`The Privacy Act of 1974 (Pt. 93—579) requires that you be given certain information in connection with your submission or’ the attached form rotated to
`a patent application or patent. Aocordingiy. pursuant to the requirements of the Act, piease be advised that:
`("ii the genera! authority for the coiiection
`of this information is 35 USS 2(b)(2); (2) furnishing of the information soiicited is voiuntary; and (.2) the principai purpose for wnich tne information is
`used by tne US Patent and Trademark Office is to process and/or examine your submission reiated to a patent appiication or patent.
`lr' you do not
`furnish tne requested information, the US Patent and Trademark Office may not be abie to process and/or examine your submission, whicn may
`result in termination of proceedings or abandonment of the appiication or expiration of the patent.
`
`The information provided by you in this form wili be subject to the foiiowing routine uses:
`
`1.
`
`The information on this form wili be treated confidentially to the extent allowed under the Freedom of information Act (5. USC. 552)
`
`and the Privacy Act (5 USIS. 552a). Records from t ..s system of records may be disciosed to the Department or’ Justice to determine
`whether tne Freedom of information Act requires disciosure of these records
`
`2.
`
`A record from this system of records may be disoiosed, as a routine use, in tne course of presenting evidence to a court. magistrate, or
`administrative tribunai, inciuding disciosures to opposing counsei in the course of se tiement negotiations.
`
`3.
`
`4.
`
`5..
`
`{5:
`
`'V'
`
`£30
`
`A record in this system of records may be disciosed, as a routine use, to a Member of Congress submitting a request invoiving an
`individuai, to whom the record pertains, when the individuai has requested assistance from the Member with respect to the subject matter of
`tne record.
`
`A record in this system of records may be disciosed, as a routine use, to a contractor of the Agency naving need for the information in
`order to perform a contract. Recipients of information shaii be required to compiy with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 USC. S
`52a(m).
`
`A record reiated to an internationai Appiication flied under the Patent Cooperation Treaty in this system or' records may be disciosed,
`as a routine use, to the internationai Bureau or' the World inteiiectual Property Organization, pursuant to the Patent C o o p eration Treaty.
`
`A record in this system of records may be disciosed, as a routine use, to another federai agency for purposes of Nationai Security
`review (35 USC. 181) and for review pursuant to the Atomic Energy Act (42 USC. 218(c} .
`
`A record from this system of records may be disciosed, as a routine use, to the Administrator, Generai Services, or his/her designee
`during an inspection of records conducted by GSA as part of that agency's responsibiiity to recommend improvements in records
`management practices and programs, under authority of 44 USC. 2904 and 2906. Such disciosure snaii be made in accordance with the
`GSA reguiations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure snaii not be used to make determinations about individuais.
`
`A record from this system of records may be disciosed, as a routine use, to the pubiic after either pubiication of the appiication pursuant
`
`to "5 USC. 1226)) or issuance of a patent pursuant to 35 USC. 151. Further, a record maybe disclosed, subject to the iimitations of 32’
`
`
`" 1.14, as a routine use, to the pubiic if tne record was tried in an application which became abandoned or in which the proceedings were
`terminated and which appiication is referenced by either a puprished appiication, an appiication open to pubiic inspections or an issued
`patent.
`
`S.
`
`A record from this system of records may be disciosed, as a routine use, to a Federai, State, or locai iaw enforcement agency, it the
`USPTO becomes aware of a vioiation or potentiai vioiation of iaw or reguiation.
`
`
`
`